CASE STUDY
Clinical Study:
Mimio Fasting Mimetic and Weight Management Outcomes
A decentralized, double-blind, placebo-controlled clinical study evaluated whether Mimio™, a fasting mimetic supplement, could support appetite control, satiety, digestive comfort, and cardiometabolic markers in overweight adults aged 55 and older. The study was conducted by People Science using the Chloe platform and published in Nature Scientific Reports.
Quick Study Snapshot
Details
Field
Study Type
Double-blind, randomized, placebo-controlled, decentralized clinical trial
Duration
14 weeks total; 2-week baseline and 8-week product/placebo period
Participants
42 evaluable participants
Population
Overweight adults age 55+ with elevated HbA1c
Primary Focus
Daily hunger and satiety
Secondary Measures
Digestive symptoms, quality of life, cognitive failures, eating behavior, metabolic bloodwork
Delivery Method
Chloe app / decentralized clinical trial platform
Sponsor
Mimio Health
Conducted By
People Science
Publication
Nature Scientific Reports, DOI: 10.1038/s41598-026-38495-7
What This Study Found
This study found that Mimio™ supplementation over 8 weeks was associated with reduced hunger, increased satiety, improved digestive comfort, and changes in select cardiometabolic markers compared with placebo. People Science reported that 91% of Mimio participants experienced improved appetite compared with 47% in the placebo group.
Why This Matters
Fasting is widely studied for its potential effects on metabolic health and healthy aging, but it can be difficult, impractical, or inappropriate for many people. Mimio™ was developed as a fasting mimetic, meaning it is designed to recreate some of the biological benefits associated with fasting without requiring food restriction.
This matters because consumers are increasingly looking for practical approaches to metabolic wellness, appetite regulation, digestive comfort, and healthy aging support.
Study Design
Objective
Evaluate the impact of Mimio™ on daily hunger and satiety.
Design
Double-blind, placebo-controlled, randomized, decentralized trial approved by Advarra IRB.
Timeline
Participants completed a 2-week baseline period followed by 8 weeks of Mimio™ or placebo use.
Intervention
Participants took one capsule daily before their first major meal.
Data Collection
Data included fasting bloodwork, hunger and satiety scales, digestive symptom questionnaires, quality of life measures, eating behavior questionnaires, and cognitive failures questionnaires.
Participant Demographics
Category
Data
42 evaluable participants
Participants
55+
Age
47.6% female, 52.4% male
Sex
Overweight adults with elevated HbA1c
Health Status
Decentralized participation from home
Primary Focus
Key Results
91%
of Mimio™ participants reported decreased mealtime appetite.
87.6%
Eliminated Bloating
83.3%
Eliminated abdominal pain
8.6%
Drop in oxidized LDL, an oxidative stress marker.
94%
Adherence
Mechanism of Action
Mimio™ is described as a fasting mimetic formulated with small molecules produced naturally by the human body during extended fasts, including spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide. The intended mechanism is to support fasting-like benefits related to appetite, satiety, metabolic health, inflammation, oxidative stress, and cardiometabolic function.
Safety + Tolerability
The case study notes that a previous pilot clinical study found the metabolites to be well tolerated.
For this section, I would strengthen it with direct adverse event data, dropout rates, and tolerability findings from the published manuscript.
Study Limitations
This section should be added more explicitly.
Suggested language:
This study included a relatively small participant group and focused on an 8-week product use period. Results should be interpreted in the context of the study population: overweight adults aged 55 and older with elevated HbA1c. Additional studies with larger and more diverse populations may help further validate these findings.
Expert Interpretation
“People Science allowed us to conduct a rigorous, gold-standard trial directly in participants' homes. The data we gathered not only confirmed our mechanism of action but showed that our formulation can deliver the benefits of fasting to the population that needs it most.”
Dr. Chris Rhodes, PhD
CEO of Mimio Health
About the Research Platform
People Science conducted the study using Chloe, its Consumer Health Learning & Organizing Ecosystem. Chloe combines a mobile app and research platform to support decentralized clinical trials, including consent, communication, data entry, reminders, monitoring, and participant engagement from home.
Frequently Asked Questions
-
The study found that Mimio™ supplementation was associated with improved appetite control, satiety, digestive comfort, and select cardiometabolic markers.
-
Yes. The study was double-blind, randomized, and placebo controlled.
-
Participants took Mimio™ or placebo for 8 weeks after a 2-week baseline period.
-
The study evaluated 42 overweight adults aged 55 and older with elevated HbA1c.
-
Reported improvements included appetite, satiety, bloating, abdominal pain, oxidized LDL, and adherence.
-
The findings were published in Nature Scientific Reports.
Other Case Studies
Book a Demo
Turn your customers’ everyday health data into your most powerful competitive asset. Explore our Chloe platform today.